Short spinal cord stimulation for stubborn nerve pain in diabetic feet
Tests spinal cord stimulation for 14 days in adults with diabetic foot nerve pain.
Key facts
- Who runs it
- Nanchong Central Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Short-term SCS for Refractory Diabetic Foot Neuropathic Pain
- Status
- Recruiting
- People taking part
- 88 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 1 Mar 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Standardized Routine Diabetic Foot Therapy
- Standard Routine Therapy + 14-day Short-term Spinal Cord Stimulation
- Record updated
- 17 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and diabetic foot nerve pain that has not improved with medicines. Some people get standard foot care alone, others also get 14 days of spinal cord stimulation.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Type 2 diabetes with Wagner grade 1-3 diabetic foot. Moderate to severe nerve pain (NRS ≥4) lasting despite treatment.
- Earlier treatment
- At least 3 months of standard non-surgical treatment: blood sugar control, nerve drugs, several pain medicines and wound care. People must be unable to have leg blood-flow surgery, still have pain after it, or refuse it. People who had spinal cord stimulation or nerve-destroying surgery before cannot join.
Main reasons for not taking part
- Spine deformity, spine infection, tumor inside the spine, or past spine surgery
- Severe bleeding disorders, body-wide infection or uncontrolled severe foot infection
- Severe heart, liver, kidney or lung problems
- Mental illness that makes assessment or follow-up hard
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age ≥18 years
- Confirmed type 2 diabetes mellitus, Wagner grade 1-3 diabetic foot
- Persistent moderate-to-severe neuropathic pain (Numeric Rating Scale, NRS ≥4) after ≥3 months of standardized conservative treatment including glycemic control, neurotrophic drugs, multi-modal analgesia and wound care
- Contraindications to lower extremity revascularization surgery, persistent pain after revascularization, or voluntary refusal of vascular surgery
- Clear consciousness, capable of completing scale assessments and multi-timepoint follow-up
- Voluntary participation with signed written informed consent
Who cannot take part
- Previous spinal cord stimulation or peripheral nerve destructive surgery
- Concurrent enrollment in other clinical trials targeting diabetic foot or chronic pain interventions
- Spinal deformity, spinal infection, intraspinal tumor or history of spinal surgery, precluding epidural electrode implantation
- Severe coagulation disorders, systemic infection or uncontrolled severe active foot infection
- Severe dysfunction of heart, liver, kidney or respiratory system, unable to tolerate minimally invasive operation
- Psychiatric disorders interfering with assessment and follow-up cooperation
- Pregnant or lactating women
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This single-center, assessor-blinded randomized controlled trial enrolls 88 patients with drug-refractory diabetic foot neuropathic pain unsuitable for revascularization surgery. Participants are randomized 1:1 to receive standard diabetic foot care alone (control) or standard care plus 14-day short-term spinal cord stimulation (intervention). The primary outcome is pain remission rate at 6 months, with repeated assessments of microcirculation, nerve function, quality of life and adverse events over 6 months. This study evaluates the efficacy and safety of short-term spinal cord stimulation and develops standardized clinical protocols for this minimally invasive therapy.
The 2 groups in the trial
- Standard Routine Therapy + 14-day Short-term Spinal Cord StimulationTreatment being tested
Patients received stSCS in addition to standard routine therapy
- Standardized Routine Diabetic Foot TherapyTreatment being tested
Patients receive standardized routine treatment for diabetic foot
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Randomized Controlled Study on 14-day Short-term Spinal Cord Stimulation Minimally Invasive Intervention for Patients With Refractory Diabetic Foot Neuropathic Pain
- Plain-language title
- Short spinal cord stimulation for stubborn nerve pain in diabetic feetGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 18 November 2026.
- Record updated
- 17 November 2026